PDS Biotechnology (PDSB) Stock Overview
A clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
PDSB Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
PDS Biotechnology Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.23 |
| 52 Week High | US$1.55 |
| 52 Week Low | US$0.22 |
| Beta | 1.55 |
| 1 Month Change | -68.62% |
| 3 Month Change | -76.94% |
| 1 Year Change | -81.40% |
| 3 Year Change | -95.89% |
| 5 Year Change | -97.95% |
| Change since IPO | -97.29% |
Recent News & Updates
PDSB: Capital Shift Toward Broader Immuno-Oncology Opportunity Could Unlock Future Upside
Analysts have reduced the 12 month price target for PDS Biotechnology to $7 from $15, citing a shift in focus that preserves PDS0101 through partnerships while concentrating limited capital on the potentially broader PDS0301 program. What’s in the News for PDS Biotechnology PDS Biotechnology scheduled an Annual Meeting of Stockholders for August 10, 2026.
PDSB: Future Clinical Data And Capital Raises Will Drive Upside Potential
Analysts have revised the price target for PDS Biotechnology to $7.50 from $9.00, citing updated assumptions around very large revenue growth expectations, a higher projected profit margin, a lower future P/E multiple, and a modestly adjusted discount rate. What’s in the News for PDS Biotechnology PDS Biotechnology filed a US$50 million follow-on equity offering of common stock as an at-the-market program, providing a potential source of additional capital.Amended Phase III Pathway And Long Patent Life Will Transform Future Cancer Care Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapy treatments for HPV16 positive cancers and other solid tumors. What are the underlying business or industry changes driving this perspective?Recent updates
PDSB: Capital Shift Toward Broader Immuno-Oncology Opportunity Could Unlock Future Upside
Analysts have reduced the 12 month price target for PDS Biotechnology to $7 from $15, citing a shift in focus that preserves PDS0101 through partnerships while concentrating limited capital on the potentially broader PDS0301 program. What’s in the News for PDS Biotechnology PDS Biotechnology scheduled an Annual Meeting of Stockholders for August 10, 2026.PDSB: Future Clinical Data And Capital Raises Will Drive Upside Potential
Analysts have revised the price target for PDS Biotechnology to $7.50 from $9.00, citing updated assumptions around very large revenue growth expectations, a higher projected profit margin, a lower future P/E multiple, and a modestly adjusted discount rate. What’s in the News for PDS Biotechnology PDS Biotechnology filed a US$50 million follow-on equity offering of common stock as an at-the-market program, providing a potential source of additional capital.Amended Phase III Pathway And Long Patent Life Will Transform Future Cancer Care Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapy treatments for HPV16 positive cancers and other solid tumors. What are the underlying business or industry changes driving this perspective?
Regulatory And Financing Risks Around HPV Cancer Program Will Eventually Reward Patience
Catalysts About PDS Biotechnology PDS Biotechnology is a clinical stage company developing immunotherapy treatments for HPV16 positive cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?HPV Positive Cancer Tailwinds And Trial Design Shifts Will Support Long Term Potential
Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapies for HPV16-positive head and neck cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
Summary PDS Biotech is a clinical-stage company focused on developing immunotherapy-based approaches for cancer, with a focus on virus-driven tumors. Their main pipeline project is PDS0101, an immunotherapy targeting the p16 protein found in HPV16-infected cells in head and neck cancer. PDSB has shown promising clinical data, with a 74% 2-year overall survival rate in a phase 2 study, but their cash position is a concern. Read the full article on Seeking AlphaPDS Biotech jumps 13% as FDA clears further development of lead asset
PDS Biotechnology (NASDAQ:PDSB), a biopharma focused on cancer immunotherapies, added 13% pre-market Monday after the company announced that a recent End-of-Phase 2 meeting with the FDA brought clarity to the late-stage development of its lead asset PDS0101. At the meeting, PDSB has submitted interim data to indicate the potential of PDS0101 against a particular form of head and neck squamous cell carcinoma (HNSCC) in combination with Merck's (MRK) anti-PD-1 therapy, Keytruda. "The interim safety and efficacy data we presented to the FDA has allowed us to move into a registrational trial ahead of our projected schedule," Chief Executive Frank Bedu-Addo remarked. The FDA has issued Fast Track designation to PDS0101/ Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer.PDS Biotechnology files for $150 mixed shelf offering
PDS Biotechnology Corp. (NASDAQ:PDSB) has filed for a $150 mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for development and commercialization of product candidates and general corporate purposes. Separately, PDS Biotechnology (PDSB) said it entered into a debt financing agreement led by Horizon Technology Finance Corporation (HRZN) for up to $35M. Seeking Alpha's Quant Rating views PDS Biotechnology (PDSB) as a hold.PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
PDS Biotechnology (NASDAQ:PDSB) traded higher on Thursday after the biotech announced that an independent panel recommended its VERSATILE-002 trial for lead asset PDS0101 in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda be continued without changes. The decision of the independent Data Monitoring Committee (DMC) was based on safety data from the study which is designed to study PDS0101 and Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer. The DMC analysis of 43 patients indicated that there were no drug discontinuations related to toxicity or treatment related Grade 3 or greater adverse events, according to the company. In May, PDS Biotech (PDSB) announced that U.K. regulators accepted its application seeking to conduct the VERSATILE-002 trial in that country.Shareholder Returns
| PDSB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -68.5% | 0.5% | 0.6% |
| 1Y | -81.4% | 35.8% | 20.1% |
Return vs Industry: PDSB underperformed the US Biotechs industry which returned 35.8% over the past year.
Return vs Market: PDSB underperformed the US Market which returned 20.1% over the past year.
Price Volatility
| PDSB volatility | |
|---|---|
| PDSB Average Weekly Movement | 21.5% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PDSB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PDSB's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 21 | Frank Bedu-Addo | www.pdsbiotech.com |
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers.
PDS Biotechnology Corporation Fundamentals Summary
| PDSB fundamental statistics | |
|---|---|
| Market cap | US$12.87m |
| Earnings (TTM) | -US$33.67m |
| Revenue (TTM) | n/a |
Is PDSB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PDSB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$33.67m |
| Earnings | -US$33.67m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 406.2% |
How did PDSB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/17 14:15 |
| End of Day Share Price | 2026/08/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PDS Biotechnology Corporation is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |